What are the potential future applications of cannabis in rheumatology, particularly for managing AS? 

As interest in cannabis grows, rheumatology research is beginning to explore its broader applications beyond symptom relief. For ankylosing spondylitis, the next frontier may involve integrating cannabinoids into multi-drug regimens, targeting inflammation with greater precision, and even disease-modifying outcomes. 

The legalisation impact has played a pivotal role in encouraging more robust studies and patient-centred approaches. Yet, research gaps persist, especially in long-term safety data, standardised formulations, and large-scale trials. Despite this, the momentum is clear. Increased awareness benefits are helping patients feel more empowered, and clinicians are more willing to discuss cannabis-based care as part of mainstream rheumatology. 

Future Possibilities in AS Care 

Here’s what emerging rheumatology research suggests might be on the horizon: 

Targeted cannabinoid therapies 

Formulations that modulate specific immune responses could alter the inflammatory cycle in the AS. 

Customised dosing systems 

Smart dispensers or AI-supported apps may help optimise timing and symptom targeting. 

Longitudinal treatment modelling 

New tools may help predict responses to cannabis over months or years, filling current research gaps. 

Mainstream clinical adoption 

As legalisation impact expands, we may see cannabis included more formally in rheumatology guidelines. 

Visit providers like LeafEase to explore how your treatment plan might benefit from advances in rheumatology research. 

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Ankylosing Spondylitis  and medical cannabis.